03/26/2024: Lab Alert: FDA Revokes EUAs for Six SARS-CoV-2 In Vitro Diagnostic Devices
Audience: Individuals Performing COVID-19 Testing
Level: Laboratory Alert
On March 21, 2024, the U.S. Food and Drug Administration (FDA) published a notice in the Federal Register about the revocation of six Emergency Use Authorizations (EUAs) of in vitro diagnostic devices for detection and/or diagnosis of COVID-19 to:
- Life Technologies Corp. (a legal entity of Thermo Fisher Scientific, Inc.), for the TaqPath COVID-19 Pooling Kit
- Bio-Rad Laboratories, Inc., for the Reliance SARS-CoV-2 RT-PCR Assay Kit
- Revvity, Inc., (on behalf of Revvity Omics (a Revvity, Inc. company that was a rebranding of PerkinElmer Genomics)), for the PerkinElmer SARS-CoV-2 RT-qPCR Reagent Kit
- bioMérieux SA, for the VIDAS SARS-CoV-2 IgM kit
- bioMérieux SA, for the VIDAS SARS-CoV-2 IgG kit
- Luminex Corp., for the xMAP SARS-CoV-2 Multi-Antigen IgG Assay
FDA revoked these EUAs under the authority of the Federal Food, Drug, and Cosmetic Act. Refer to the FDA Letter of Revocation for more information.
Opt in to receive updates from the CDC Laboratory Outreach Communication System.
Questions
- If you are a clinical or public health laboratory professional, contact LOCS.
- For media inquiries, contact the CDC Newsroom.
- For all other questions, contact CDC-INFO.
Thank you,
The Laboratory Outreach Communication System
Laboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)
Center for Laboratory Systems and Response (CLSR)
Centers for Disease Control and Prevention (CDC)